Drug intelligence / Profile preview

alpha-Pyrrolidinononanophenone

Development stage: Unknown
Modality: Small Molecules

Overview

alpha-Pyrrolidinononanophenone is a small molecule drug with a molecular formula of C19H29NO. It has been investigated for its potential use in various conditions, including actinic keratosis, breast cancer, liver cancer, melanoma, psoriasis and psoriatic disorders, and solid tumors. Its mechanism of action involves causing neuronal cell apoptosis.

Other names: Nonanophenone, 2-(1-pyrrolidinyl)-1-Phenyl-2-(1-pyrrolidinyl)-1-nonanone

Beyond the preview

Go deeper on alpha-Pyrrolidinononanophenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-Pyrrolidinononanophenone.

Explore the full profile